MILWAUKEE, Dec. 03, 2015 (GLOBE NEWSWIRE) -- We are investigating the Board of Directors of ARPI for possible breaches of fiduciary duty and other violations of state law in connection with the sale of ARPI to AMH.
Click here to learn how to join the action: http://www.ademilaw.com/case/arpi or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
ARPI long-term financial outlook is improving and yet ARPI shareholders will receive only 1.135 common shares or limited partnership units of AMH. AMH is well aware of ARPI improving financial metrics and is purchasing ARPI at a substantial discount. The merger agreement unreasonably limits prospective bids for ARPI by (i) prohibiting solicitation of any further bids, and (ii) imposing a termination penalty should ARPI receive and accept a superior bid. ARPI insiders, their affiliates and other majority shareholders own significant voting stock, and will receive millions of dollars as part of change of control arrangements, and therefore can unduly influence a sale of ARPI not in the best interests of non-insiders. Our investigation centers on the conduct of ARPI Board of Directors, who have unanimously approved the transaction, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for ARPI given its current financial condition and prospects.
If you own common shares or limited partnership units in ARPI and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or http://www.ademilaw.com/case/arpi.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Ademi & O’Reilly, LLP Guri Ademi 3620 East Layton Ave. Cudahy, WI 53110 Toll Free: (866) 264-3995 Fax: (414) 482-8001 www.ademilaw.com


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Anta Sports Expands Global Footprint With Strategic Puma Stake
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



